Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial-Reference-Cited by-同舟云学术

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial

Published:2021-03-10 Issue:6 Volume:23 Page:1357-1369
ISSN:1462-8910
Container-title:Colorectal Disease
language:en
Short-container-title:Colorectal Dis

Author:

Karoui Mehdi¹^ORCID,Gallois Claire²,Piessen Guillaume³,Legoux Jean‐Louis⁴,Barbier Emilie⁵,De Chaisemartin Cecile⁶,Lecaille Cedric⁷,Bouche Olivier⁸,Ammarguellat Hanifa⁹,Brunetti Francesco¹⁰,Prudhomme Michel¹¹,Regimbeau Jean‐Marc¹²,Glehen Olivier¹³,Lievre Astrid¹⁴,Portier Guillaume¹⁵,Hartwig Johannes¹⁶,Goujon Gael¹⁷,Romain Benoit¹⁸,Lepage Come¹⁹,Taieb Julien²,Ainseba N.,Alcaraz L.,Audemar F.,Bachet J. B.,Bardier A.,Baumgaertner I.,Luciani A.,Bège T.,Ben Abdelghani M.,Bourgeois V.,Brigand C.,Couteau C.,Champetier C.,Chauvenet M.,Debourdeau P.,Deguelte S.,Poizat F.,Sarran A,Deplanque G.,Olivier D.,Duluc M.,Faucheron J. L.,François Y.,Freddy M.,Gasmi M.,Gornet J. M.,Gualtierotti M.,Lacaze L.,Lagasse J. P.,Lepere C.,Loriau J.,Malaurie E.,Manfredi S.,Mauvais F.,Meunier B.,Mineur L.,N’Guyen S.,Obled S.,Oden Gangloff A.,Ollier J. C.,Pelletier A. L.,Pere Verge D.,Peschaud F.,Pezet D.,Ramdani M.,Ries‐guye P.,Rougier P.,Rullier E.,Sabbagh C.,Saudemont A.,Seitz J. F.,Sobhani I.,Tessier W.,Tougeron D.,

Affiliation:

1. Department of Digestive and Oncological Surgery AP‐HP; Hôpital Européen Georges Pompidou Paris University Paris France

2. Department of Hepato‐gastroenterology and Digestive Oncology Hôpital Européen Georges Pompidou, AP‐HP Paris University Paris France

3. Department of Digestive and Oncological Surgery Lille University Hospital Lille France

4. Department of Hepato‐gastroenterology and Digestive Oncology CHR La Source Orléans France

5. Biostatistics, FFCD, EPICAD INSERM LNC‐UMR 1231 University of Burgundy and Franche Comté Dijon France

6. Department of Digestive Surgery Institut Paoli Calmettes Marseille France

7. Department of Oncology Polyclinique Bordeaux Nord Bordeaux France

8. Department of Digestive Oncology CHU Robert Debré Reims France

9. Department of Medical Oncology CH Beauvais Beauvais France

10. Department of Digestive Surgery AP‐HP CHU Henri Mondor Créteil France

11. Department of Digestive Surgery CHU Carémeau Nîmes France

12. Department of Digestive Surgery Amiens University Hospital France

13. Department of Digestive Surgery CHU Lyon Sud Lyon France

14. Department of Gastroenterology CHU Rennes, Rennes 1 University Rennes France

15. Department of Digestive Surgery CHU Rangueil Toulouse France

16. Department of GastroenterologyInfirmerie Protestante Caluire‐et‐Cuire France

17. Department of Gastroenterology Paris VII, AP‐HP BCHU Bichat Paris France

18. Department of Digestive Surgery CHU Hautepierre Strasbourg France

19. Hepato‐gastroenterology and Digestive Oncology Department FFCD, EPICAD INSERM LNC‐UMR 1231 CHU Dijon University of Burgundy and Franche Comté Dijon France

Funder

Ministère de la Santé

Publisher

Wiley

Subject

Gastroenterology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/codi.15585

Reference33 articles.

1. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study

2. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

3. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial